Quick Summary

Schizophyllum commune, commonly known as Split Gill, is a widely distributed mushroom containing diverse bioactive compounds such as polysaccharides (notably β-glucans), triterpenoids, proteins, and ergosterol. Research suggests it may have immunomodulatory, antioxidant, anti-inflammatory, and antimicrobial properties. Emerging studies explore its polysaccharides’ potential roles in managing chronic inflammation, cancer, skin care, and gut health. However, most evidence is preclinical or mechanistic, with limited clinical trials. Clinical guidelines indicate that Schizophyllum commune can cause allergic bronchopulmonary mycosis, a fungal hypersensitivity lung condition distinct from Aspergillus-related disease. Overall, clinical benefits and risks require further elucidation.

What Is It?

Split Gill (Schizophyllum commune) is a type of mushroom found worldwide. It is characterized by a unique split gill structure on its underside. This mushroom produces various bioactive substances including polysaccharides, triterpenoids, proteins, and ergosterol, which are under investigation for their potential health-related activities.

Traditional Uses

Traditionally, Schizophyllum commune has been used in some cultures for its nutritional and functional properties, although it is not commonly used in mainstream herbal medicine. Its use is primarily associated with edible mushroom preparations and ethnic therapeutic applications.

Active Compounds

  • Polysaccharides: Especially β-glucans, which are known for immune modulation.
  • Triterpenoids: Bioactive compounds with possible anti-inflammatory effects.
  • Proteins: Contributing to nutritional and antimicrobial properties.
  • Ergosterol: A fungal sterol with potential biological activities.

Potential Benefits with Evidence Levels

  • Immunomodulation and Chronic Inflammation Management

    Evidence level: Preclinical and review-level mechanistic evidence

    Bioactive polysaccharides like β-glucans from Schizophyllum commune may modulate immune cells and signaling pathways, showing anti-inflammatory activity potentially beneficial for chronic inflammation (Xiaoying et al., 2025).
  • Anti-Cancer Potential

    Evidence level: Preclinical and literature review

    Mushroom-derived compounds including those from Schizophyllum commune have been reviewed for anti-tumor effects attributed to immune enhancement and direct cytotoxicity; however, clinical evidence is lacking (Górska-Jakubowska et al., 2025; Ying & Hao, 2023).
  • Antioxidant and Skin Care Applications

    Evidence level: Review-based mechanistic and functional evidence

    β-glucans found in Schizophyllum commune exhibit antioxidant, barrier repair, moisturizing, and anti-inflammatory effects relevant to potential skin care uses (Feng et al., 2025).
  • Nutritional and Functional Properties

    Evidence level: Descriptive and analytical studies

    Proteins and bioactive compounds in this mushroom contribute to its nutritional value and may support antimicrobial and immunomodulatory functions (Ionescu et al., 2025).
  • Allergic Bronchopulmonary Mycosis (ABPM) Related to Schizophyllum commune Exposure

    Evidence level: Clinical observational and guideline-based evidence

    Schizophyllum commune is recognized as a causative agent in allergic bronchopulmonary mycosis, a hypersensitivity lung condition requiring clinical diagnosis and management (Agarwal et al., 2024; Asano & Oguma, 2025).

Side Effects

Adverse effects mainly involve allergic or hypersensitivity respiratory reactions, such as allergic bronchopulmonary mycosis. There is no explicit evidence from human studies of systemic toxicity or other side effects related to ingestion or supplementation.

Drug Interactions

Currently, no documented drug interactions specific to Schizophyllum commune have been identified.

Who Should Avoid It

Individuals with known fungal hypersensitivity or respiratory allergies should exercise caution with exposure to Schizophyllum commune. Due to limited safety data, its use during pregnancy and breastfeeding is not recommended without medical supervision.

Evidence Limitations

The majority of evidence supporting Schizophyllum commune’s potential benefits comes from preclinical, mechanistic, or review-based studies. There is a lack of robust randomized controlled trials or comprehensive clinical studies evaluating efficacy and safety in humans. The clinical relevance of many bioactivities remains unclear. Additionally, the potential for allergenicity and fungal hypersensitivity syndromes necessitates cautious use. Further well-designed human research is needed to confirm health effects and safety profiles.

References

Last Reviewed

April 2024

Disclaimer: This information is intended for educational purposes only and should not replace professional medical advice. Consult a healthcare provider before starting any new herb or supplement, especially if you have existing health conditions, are pregnant, breastfeeding, or taking medications.